GT199900140A - Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos. - Google Patents

Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos.

Info

Publication number
GT199900140A
GT199900140A GT199900140A GT199900140A GT199900140A GT 199900140 A GT199900140 A GT 199900140A GT 199900140 A GT199900140 A GT 199900140A GT 199900140 A GT199900140 A GT 199900140A GT 199900140 A GT199900140 A GT 199900140A
Authority
GT
Guatemala
Prior art keywords
derivatives
alquinils
ona
quinolin
target agents
Prior art date
Application number
GT199900140A
Other languages
English (en)
Inventor
Susan Deborah La Greca
Joseph Peter Lyssikatos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199900140A publication Critical patent/GT199900140A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ESTA INVENCIÒN SE REFIERE A UNA SERIE DE DERIVADOS DE QUINOLIN2ONA (REPRESENTADOS ABAJO COMO FÒRMULA I , DONDE LAS LETRAS "R" ENUMERADAS REPRESENTAN POSIBLES GRUPOS SUSTITUYENTES ALQUINILSUSTITUIDOS; ÙTILES EN EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS EN MAMÌFEROS, ESPECIALMENTE EN EL HOMBRE.
GT199900140A 1998-08-27 1999-08-24 Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos. GT199900140A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9814598P 1998-08-27 1998-08-27

Publications (1)

Publication Number Publication Date
GT199900140A true GT199900140A (es) 2001-02-14

Family

ID=22267481

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199900140A GT199900140A (es) 1998-08-27 1999-08-24 Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos.

Country Status (40)

Country Link
US (3) US6150377A (es)
EP (1) EP1107963B1 (es)
JP (1) JP3495706B2 (es)
KR (1) KR20010072991A (es)
CN (1) CN1314904A (es)
AP (1) AP2001002079A0 (es)
AT (1) ATE321037T1 (es)
AU (1) AU4925499A (es)
BG (1) BG105365A (es)
BR (1) BRPI9913138B8 (es)
CA (2) CA2578326C (es)
CO (1) CO5130017A1 (es)
CZ (1) CZ2001660A3 (es)
DE (1) DE69930518T2 (es)
DZ (1) DZ2880A1 (es)
EA (1) EA200100135A1 (es)
EE (1) EE200100118A (es)
ES (1) ES2259237T3 (es)
GE (1) GEP20033001B (es)
GT (1) GT199900140A (es)
HK (1) HK1039123A1 (es)
HR (1) HRP20010142A2 (es)
HU (1) HUP0103228A3 (es)
ID (1) ID27562A (es)
IL (1) IL141239A0 (es)
IS (1) IS5818A (es)
MA (1) MA26680A1 (es)
NO (1) NO20010964L (es)
NZ (1) NZ509372A (es)
OA (1) OA11645A (es)
PA (1) PA8480101A1 (es)
PE (1) PE20000986A1 (es)
PL (1) PL346426A1 (es)
SK (1) SK2442001A3 (es)
SV (1) SV1999000141A (es)
TN (1) TNSN99162A1 (es)
TR (1) TR200101343T2 (es)
UY (1) UY25682A1 (es)
WO (1) WO2000012499A1 (es)
ZA (1) ZA200101173B (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114503A1 (en) * 1997-06-16 2003-06-19 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
CN1170538C (zh) * 1998-07-06 2004-10-13 詹森药业有限公司 供治疗关节病的法呢基(Farnesyl)蛋白质转移酶抑制剂
CZ2001660A3 (cs) * 1998-08-27 2002-05-15 Pfizer Products Inc. Alkynylsubstituované chinolin-2-ony, farmaceutické kompozice a způsoby léčení na jejich bázi a způsob výroby těchto sloučenin
DE69923849T2 (de) * 1998-08-27 2006-01-12 Pfizer Products Inc., Groton Quinolin-2-on-derivate verwendbar als antikrebsmittel
AP2001002241A0 (en) 1999-02-11 2001-09-30 Pfizer Prod Inc Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents.
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
DE60130976T2 (de) 2000-02-24 2008-07-17 Janssen Pharmaceutica N.V. Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
AU2001293835A1 (en) * 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
AU2001293826A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
AU2001293829A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-((substituted phenyl)methyl)-quinoline and quinazoline derivatives
ES2313991T3 (es) * 2000-09-25 2009-03-16 Janssen Pharmaceutica Nv Derivados de 6-heterociclilmetil-quinolina y quinazolina que inhiben la farnesil transferasa.
ATE434615T1 (de) 2000-11-21 2009-07-15 Janssen Pharmaceutica Nv Farnesyltransferase hemmende benzoheterocyclische derivate
EP1395577A1 (en) 2000-12-19 2004-03-10 Pfizer Products Inc. Crystal forms of 6- (4-chloro-phenyl)-hydroxy-(-3-methyl-3h-imidaol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
JP4351445B2 (ja) * 2000-12-27 2009-10-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する４−置換−キノリンおよびキナゾリン誘導体
US6645966B2 (en) * 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
SI1373255T1 (es) 2001-03-12 2005-08-31 Janssen Pharmaceutica Nv
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
AU2002257114A1 (en) * 2001-04-06 2002-10-21 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
WO2002098425A1 (en) * 2001-06-04 2002-12-12 Cytovia, Inc. Substituted 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2003000266A1 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinolines and uses thereof
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
WO2003051880A1 (en) 2001-12-19 2003-06-26 Janssen Pharmaceutica N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
US7241777B2 (en) 2002-03-22 2007-07-10 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
CA2481480C (en) 2002-04-15 2011-04-12 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
AU2003286321A1 (en) * 2002-12-19 2004-07-14 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
JP4691041B2 (ja) 2003-11-20 2011-06-01 チルドレンズ ホスピタル メディカル センター Ｇｔｐアーゼ阻害剤および使用方法
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
JP2007530654A (ja) * 2004-03-30 2007-11-01 ファイザー・プロダクツ・インク シグナル伝達阻害剤の組合せ
WO2006021886A1 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
ES2341351T3 (es) 2004-08-26 2010-06-18 Pfizer, Inc. Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina cinasas.
EP1784396B8 (en) * 2004-08-26 2011-04-20 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
DK2362218T3 (en) 2004-11-05 2014-11-17 Janssen Pharmaceutica Nv Methods for monitoring the effectiveness of farnesyl transferase
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
AU2006275528B2 (en) 2005-07-29 2012-03-08 Children's Hospital Medical Center GTPase inhibitors and methods of use and crystal structure of Rac-1 GTPase
CA2621371C (en) 2005-09-07 2018-05-15 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
JP5055284B2 (ja) 2005-09-20 2012-10-24 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー インシュリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
JP2009521470A (ja) 2005-12-23 2009-06-04 リンク メディシン コーポレイション シヌクレイン障害の治療
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
US7414050B2 (en) 2006-04-20 2008-08-19 Janssen Pharmaceutica, N.V. Inhibitors of c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
BRPI0710548B8 (pt) 2006-04-20 2021-05-25 Janssen Pharmaceutica Nv inibidores de c-fms cinase, composição farmacêutica e forma de dosagem farmacêutica
MEP43308A (en) 2006-05-09 2011-02-10 Pfizer Prod Inc Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
SI2056874T1 (sl) 2006-08-21 2012-12-31 F. Hoffmann-La Roche Ag Terapija tumorjev s protitelesom proti vegf
US20100184803A1 (en) * 2007-03-09 2010-07-22 Link Medicine Corporation Treatment of Lysosomal Storage Diseases
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US8232402B2 (en) 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
AU2009313927A1 (en) 2008-11-13 2010-05-20 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109572A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013166043A1 (en) 2012-05-02 2013-11-07 Children's Hospital Medical Center Rejuvenation of precursor cells
IN2015DN00659A (es) 2012-08-07 2015-06-26 Janssen Pharmaceutica Nv
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
EA201890512A1 (ru) 2015-08-17 2018-09-28 Кура Онколоджи, Инк. Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы
WO2017096165A1 (en) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
US20190119758A1 (en) 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
BR112019009000A2 (pt) 2016-11-03 2019-07-16 Kura Oncology Inc método para tratar um carcinoma refratário, método de tratamento de scchn, método de tratamento de carcinoma de células escamosas, método de tratamento para scc
EP3579872A1 (en) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
TWI693074B (zh) 2017-02-21 2020-05-11 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
WO2019032489A1 (en) 2017-08-07 2019-02-14 Kura Oncology, Inc. METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
CA3117968A1 (en) 2018-11-01 2020-05-07 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
AU2019403379A1 (en) 2018-12-21 2021-07-15 Kura Oncology, Inc. Therapies for squamous cell carcinomas
WO2020180663A1 (en) 2019-03-01 2020-09-10 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
SG11202110472WA (en) 2019-03-29 2021-10-28 Kura Oncology Inc Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
US20220168296A1 (en) 2019-04-01 2022-06-02 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2020223583A1 (en) 2019-05-02 2020-11-05 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DK1162201T3 (da) * 1995-12-08 2006-07-17 Janssen Pharmaceutica Nv Farnesylproteintransferaseinhiberende (imidazol-5-yl)methyl-2-quinolinonderivater
CZ2001660A3 (cs) * 1998-08-27 2002-05-15 Pfizer Products Inc. Alkynylsubstituované chinolin-2-ony, farmaceutické kompozice a způsoby léčení na jejich bázi a způsob výroby těchto sloučenin

Also Published As

Publication number Publication date
SK2442001A3 (en) 2002-10-08
US6294552B1 (en) 2001-09-25
OA11645A (en) 2004-11-16
HUP0103228A3 (en) 2003-01-28
BG105365A (en) 2001-11-30
IS5818A (is) 2001-01-19
DE69930518D1 (de) 2006-05-11
GEP20033001B (en) 2003-06-25
AP2001002079A0 (en) 2001-03-31
BR9913138B1 (pt) 2013-11-05
HK1039123A1 (zh) 2002-04-12
NZ509372A (en) 2003-08-29
EP1107963B1 (en) 2006-03-22
CZ2001660A3 (cs) 2002-05-15
DE69930518T2 (de) 2006-09-21
TNSN99162A1 (fr) 2005-11-10
ATE321037T1 (de) 2006-04-15
BR9913138A (pt) 2001-05-08
BRPI9913138B8 (pt) 2016-05-17
WO2000012499A1 (en) 2000-03-09
ES2259237T3 (es) 2006-09-16
EE200100118A (et) 2002-06-17
ZA200101173B (en) 2002-04-12
CN1314904A (zh) 2001-09-26
PA8480101A1 (es) 2003-06-30
DZ2880A1 (fr) 2003-12-15
PE20000986A1 (es) 2000-09-30
JP2002523504A (ja) 2002-07-30
HUP0103228A2 (hu) 2002-02-28
CA2341690C (en) 2007-04-17
NO20010964D0 (no) 2001-02-26
IL141239A0 (en) 2002-03-10
TR200101343T2 (tr) 2001-09-21
CA2578326A1 (en) 2000-03-09
NO20010964L (no) 2001-04-26
KR20010072991A (ko) 2001-07-31
HRP20010142A2 (en) 2002-02-28
JP3495706B2 (ja) 2004-02-09
CA2341690A1 (en) 2000-03-09
SV1999000141A (es) 2000-07-06
CO5130017A1 (es) 2002-02-27
EA200100135A1 (ru) 2001-08-27
US6150377A (en) 2000-11-21
PL346426A1 (en) 2002-02-11
EP1107963A1 (en) 2001-06-20
US20020128287A1 (en) 2002-09-12
MA26680A1 (fr) 2004-12-20
US6579887B2 (en) 2003-06-17
AU4925499A (en) 2000-03-21
ID27562A (id) 2001-04-12
UY25682A1 (es) 2000-03-31
CA2578326C (en) 2009-11-24

Similar Documents

Publication Publication Date Title
GT199900140A (es) Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos.
GT199900055A (es) Nuevas dihidropirimidinas2 heterocìclicamente sustituidas.
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
GT199600026A (es) Isotiazolonas
HN1998000036A (es) Compuesto de pirazina
GT199900053A (es) Pirazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de la disfuncion sexual.
HN2000000051A (es) Derivados heterociclicos utiles como agentes anticancerosos
HN1998000168A (es) Derivados de la tienapirimidina y de la tienapiridina utiles como agentes anticancerigenos.
ES2161290T3 (es) Derivados de quinazolina.
BR9802570A (pt) Caixa de câmbio
HN2000000268A (es) Compuestos , composiciones y metodos para estimular el crecimiento y elongacion de neuronas
GT200000014A (es) Derivados de quinolin - 2 - ona sustituidos con heteroarilo utiles como agentes anticancerigenos.
AR026410A1 (es) ''2-aril-3-(heteroaril)-imidazo[1,2-a]pirimidinas sustituidas, y las composiciones y metodos farmaceuticos relacionados
PA8514401A1 (es) Nuevos derivados de piperazina
AR026938A1 (es) Combinaciones de productos activos fungicidas.
ES2183331T3 (es) Inhibidores de sulfamida-metaloproteasa.
NO974321L (no) Nodulisporsyrederivater
HN1998000088A (es) Tratamiento de resistencia a la insulina
GT200000001A (es) Derivados de eter propargilico novedosos.
CO5190674A1 (es) Tratamiento de desordenes neuroticos desordenes neuroticos
SE9801494D0 (sv) Novel use
BR0115963A (pt) Derivados de benzofurano e benzotiofeno
ES2159054T3 (es) Compuestos di-terc-butil-fenolicos que contienen azufre utiles como agentes antiinflamatorios.
GT199900193A (es) Combinaciones fungicidas que comprenden tieno [2,3-d] pirimidin-4-ona.
ES2195158T3 (es) Amidas de alfa-aminoacidos, su preparacion y el uso terapeutico de las mismas.